Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

STADA Arzneimittel AG: Voluntary public takeover offer by Bain Capital and Cinven not successful

  • 26/06/2017
  • Ad hoc Release
  • Investor News

Bad Vilbel, June 26, 2017 –

Nidda Healthcare Holding AG, the acquiring company of Bain Capital and Cinven, announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on June 22, 2017, 65.52 percent of the STADA shares outstanding have been tendered under the voluntary public takeover offer made for all the company’s outstanding shares. Consequently, the minimum acceptance threshold, which the bidder reduced from originally 75.0 to 67.5 percent on June 7, 2017, has not been reached.


Regardless of the termination of the takeover offer, STADA has confirmed its growth targets for the current financial year 2017. The Executive Board continues to assume Group sales adjusted for currency and portfolio effects of Euro 2.280 to 2.350 billion, adjusted EBITDA of Euro 430 to 450 million and adjusted net income of Euro 195 to 205 million. The termination of the takeover offer will also have no effect on the medium-term growth targets for 2019 announced on March 17, 2017. For 2019, the Executive Board continues to expect adjusted Group sales of Euro 2.650 to 2.700 billion, adjusted EBITDA of Euro 570 to 590 million and adjusted net income of Euro 250 to 270 million.

Contact:
STADA Arzneimittel AG / Investor Relations / Leslie Iltgen / Stadastraße 2–18 / 61118 Bad Vilbel – Germany /
Tel.: +49 (0) 6101 603-173 / Fax: +49 (0) 6101 603-215 / E-mail: [email protected]